Filing Details
- Accession Number:
- 0001209191-23-037194
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-14 19:04:32
- Reporting Period:
- 2023-06-12
- Accepted Time:
- 2023-06-14 19:04:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1679363 | Morphic Holding Inc. | MORF | Pharmaceutical Preparations (2834) | 473878772 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1779978 | P. Praveen Tipirneni | C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-06-12 | 840 | $4.32 | 14,776 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-06-12 | 840 | $63.01 | 13,936 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy Common Stock) | Disposition | 2023-06-12 | 840 | $0.00 | 840 | $4.32 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
368,337 | 2028-12-14 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder dated September 16, 2022.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This option is fully vested.